Skip to main content

Only KISQALI offers single-strength tablets for simple dose reductions1

With simple dose reductions, eliminate the need for new mid-cycle prescriptions and additional costs
Dose reductions for KISQALI® (ribociclib)


  • KISQALI is given as 600 mg (3 x 200-mg tablets) orally once daily (3 weeks on, 1 week off) with either:

    • An AI once daily (continuously); in premenopausal patients and men, an LHRH agonist should be administered according to current clinical practice guidelines2; or

    • Fulvestrant 500 mg intramuscularly on Days 1, 15, and 29, and once monthly thereafter for postmenopausal patients or men. In male patients, an LHRH agonist should be administered according to current clinical practice guidelines

  • Dose adjustments for adverse reactions should be made in a stepwise order by reducing the number of tablets taken

  • Dose modification of KISQALI is recommended based on individual safety and tolerability

  • If dose reduction below 200 mg/day is required, discontinue treatment

  • KISQALI can be taken with or without food

Video thumbnail

Expert perspective on dosing and patient adherence in HR+/HER2- mBC

“…the single-tablet strength allows for simple dose adjustments, and to me, that is game changing.” —Nick McAndrew, MD

Simple dose adjustments1

A guide for treating with KISQALI

KISQALI Treatment Guide

A guide to treating with KISQALI for your patients with HR+/HER2- metastatic breast cancer. Includes KISQALI overall survival data, as well as dosing, safety, and patient support.

AI=aromatase inhibitor; ALT=alanine aminotransferase; ANC=absolute neutrophil count; AST=aspartate aminotransferase; BSA=body surface area; CTCAE=Common Terminology Criteria for Adverse Events; CYP3A=cytochrome P450, family 3, subfamily A; ECG=electrocardiogram; ILD=interstitial lung disease; IV=intravenous; LHRH=luteinizing hormone-releasing hormone; LLN=lower limit of normal; mBC=metastatic breast cancer; QTcF=QT interval corrected by Fridericia's formula; SCAR=severe cutaneous adverse reaction; SJS=Stevens-Johnson syndrome; TB=total bilirubin; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.

References: 1. Kisqali [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Kisqali Femara Co-Pack [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.